Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts payable	413,000)	364,900)	303,900)	195,000)	155,139)
Product revenue accruals	1,618,900)	1,716,400)	1,300,800)	847,400)	781,903)
Payroll and benefits	352,100)	295,000)	246,500)	191,300)	169,387)
Research, development and commercial contract costs	319,200)	265,200)	198,700)	171,600)	136,704)
Royalty payable	271,000)	237,600)	215,000)	200,400)	165,404)
Tax related accruals	161,100)	99,500)	123,300)	211,300)	104,173)
Other	66,300)	41,600)	42,400)	56,600)	47,400)
Accrued expenses	2,788,600)	2,655,300)	2,126,700)	1,678,600)	1,404,971)
Milestones payable	32,500)	222,500)	—)	—)	—)
Contract liabilities	206,800)	170,300)	159,600)	171,700)	191,519)
Current operating lease liabilities	87,100)	33,100)	48,600)	33,300)	10,521)
Current finance lease liabilities	5,200)	50,600)	40,800)	46,900)	42,434)
Other	31,400)	50,700)	62,500)	16,500)	72,949)
Other current liabilities	363,000)	527,200)	311,500)	268,400)	317,423)
Current liabilities	3,564,600)	3,547,400)	2,742,100)	2,142,000)	1,877,533)
Long-term operating lease liabilities	1,544,400)	348,600)	379,500)	377,400)	350,463)
Long-term finance lease liabilities	112,800)	376,100)	430,800)	509,800)	539,042)
Tax-related liabilities	698,600)	681,400)	452,800)	—)	—)
Contingent consideration	76,900)	77,400)	114,400)	186,500)	189,600)
Other	126,300)	118,900)	118,600)	116,800)	108,355)
Other long-term liabilities	901,800)	877,700)	685,800)	303,300)	297,955)
Long-term liabilities	2,559,000)	1,602,400)	1,496,100)	1,190,500)	1,187,460)
Total liabilities	6,123,600)	5,149,800)	4,238,200)	3,332,500)	3,064,993)
Preferred stock, $0.01 par value; none issued and outstanding	—)	—)	—)	—)	—)
Common stock, $0.01 par value	2,600)	2,600)	2,600)	2,500)	2,599)
Additional paid-in capital	6,672,400)	7,449,700)	7,386,500)	6,880,800)	7,894,027)
Accumulated other comprehensive income (loss)	127,800)	(14,300)	800)	15,900)	(68,480)
Retained earnings	9,606,800)	10,142,400)	6,522,800)	3,200,800)	858,669)
Shareholders’ equity	16,409,600)	17,580,400)	13,912,700)	10,100,000)	8,686,815)
Total liabilities and shareholders’ equity	22,533,200)	22,730,200)	18,150,900)	13,432,500)	11,751,808)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Balance Sheet: Liabilities and Stockholders’ Equity